Conference Call to discuss Updated Data from Part B of the DeFianCe Study March 26, 2025 8:00 AM ET. Company Participants. Douglas Onsi - President ...

Introduction: One of the primary obstacles faced by individuals with advanced colorectal cancer (CRC) is the potential development of acquired chemoresistance as the disease advances. Studies have ...

Every dollar of federal-funded research generates an additional $2.56 in economic activity. Because of the cuts by DOGE, ...

Nadunolimab's additional potential in mitigating neuropathy demonstrated by data from Cantargia's CESTAFOUR and CAPAFOUR ...

Good morning, and welcome to Agenus Inc.'s fourth-quarter and year-end 2024 earnings conference call. Currently, all participants are in a listen-only mode. A question-and-answer session will follow ...

Trastuzumab botidotin has met the primary endpoints of its pivotal Phase 2 trial for 3L+ advanced HER2+ BC based on results from the primary analysis, which the Company used to submit an NDA to the ...

In this video, Michael Cecchini, MD, discusses the significance of results from the phase 3 BREAKWATER trial, which were presented at ASCO Gastrointestinal Cancers Symposium.

Experts discuss how to facilitate open communication among the patient, caregivers, and the multidisciplinary team to ensure comprehensive care and alignment on treatment goals.

昨天（3月24日）晚间，科伦博泰发布了2024年度业绩报告。报告期内，公司营收19.33亿元，同比增长25.5%；毛利12.74亿元，同比增长67.8%；研发支出12.06亿元，同比增长17%；年度亏损2.67亿元，同比减少53.5%；调整后年度亏损 ...